ACT | Jotup

First of its Kind Colorectal Cancer Data from Prospective GALAXY Study Released at ESMO; Demonstrates Signatera's Ability to Predict Overall Survival

Retrieved on:

Saturday, September 14, 2024

GALAXY is one of the largest and most comprehensive prospective studies of circulating tumor DNA (ctDNA) testing in resectable colorectal cancer (CRC).

Key Points:

GALAXY is one of the largest and most comprehensive prospective studies of circulating tumor DNA (ctDNA) testing in resectable colorectal cancer (CRC).
The data also demonstrates Signatera’s ability to predict adjuvant chemotherapy (ACT) benefit in resectable CRC, with ctDNA clearance as an indicator of a superior survival benefit compared to no clearance.
This 10x advantage in overall survival compares favorably to all known guideline-recommended biomarkers that have HRs for overall survival in a range of 1-4.
“Introducing 36-month, first-of-its-kind data on overall survival is an important milestone that reinforces the potential to improve outcomes for patients diagnosed with colorectal cancer.

Advanced eClinical Training Partners with The Education Fund to Expand Educational Opportunities for Healthcare Workers

Retrieved on:

Friday, September 13, 2024

Advanced eClinical Training (ACT), a leader in online career certification training, has teamed up with the SEIU-UHW West & Joint Employer Education Fund (The Education Fund) , an employer-paid benefit that provides education, training, and career advice services to union members across the healthcare sector.

Key Points:

Advanced eClinical Training (ACT), a leader in online career certification training, has teamed up with the SEIU-UHW West & Joint Employer Education Fund (The Education Fund) , an employer-paid benefit that provides education, training, and career advice services to union members across the healthcare sector.
“Partnering with The Education Fund allows us to make a real impact on the careers of thousands of healthcare professionals,” said Shabnam Safarzadeh, President and CEO of ACT.
The Education Fund is supported by collectively bargained employer contributions and is designed to offer healthcare union members education and training services at no cost.
The partnership with The Education Fund further strengthens the accessibility of these career-changing programs for healthcare workers across the nation.

Indiana Wesleyan University Partners with Advanced eClinical Training to Enhance Allied Health Education and Offerings

Retrieved on:

Friday, September 13, 2024

Education, Health, Other Health, General Health, Other Education, Continuing, Training, ACT, IWU, Indiana Wesleyan University, Knowledge, Hospital, Student, Workforce, Partnership, Nursing

Advanced eClinical Training (ACT), a leading provider of online short-term healthcare training is proud to announce its partnership with Indiana Wesleyan University (IWU) aimed to enhance its allied health education and offerings.

Key Points:

Advanced eClinical Training (ACT), a leading provider of online short-term healthcare training is proud to announce its partnership with Indiana Wesleyan University (IWU) aimed to enhance its allied health education and offerings.
As the healthcare industry continues to evolve, the demand for skilled professionals in allied health roles has never been greater.
These programs are designed to equip students with the credentials and certificates necessary to succeed in high-skill, high-wage allied health careers.
"We are thrilled to partner with Indiana Wesleyan University in advancing career-focused training programs in healthcare," said Cassidy Floyd, Director of Strategic Partnerships at Advanced eClinical Training (ACT).

Allison Transmission Equips Hydrogen-Fueled Truck Showcased at COMVEC

Retrieved on:

Thursday, September 12, 2024

Hydrogen, ACT, Allison Transmission, Commercial vehicle, Southwest Research Institute, Gasoline, Propane, Product engineering, Natural gas, Torque, Transport, Congress, ICE, European emission standards, EPA, Overalls, SAE International, CO2

INDIANAPOLIS, Sept. 12, 2024 /PRNewswire/ -- Allison Transmission is pleased to announce the integration of the Allison 4000 Series™ transmission with a Class 8 truck equipped with a Hydrogen Internal Combustion Engine (H2-ICE) displayed by Southwest Research Institute (SwRI) at SAE International's Commercial Vehicle Engineering Congress (COMVEC) in Schaumburg, Illinois. The H2-ICE vehicle demonstrates emissions control capable of outperforming EPA/CARB 2027 and Euro 7 criteria pollutant emissions standards.

Key Points:

Allison-equipped Hydrogen Internal Combustion Engine (H2-ICE) truck demonstrates emissions control capable of outperforming upcoming emissions standards in the U.S. and Europe.
INDIANAPOLIS, Sept. 12, 2024 /PRNewswire/ -- Allison Transmission is pleased to announce the integration of the Allison 4000 Series™ transmission with a Class 8 truck equipped with a Hydrogen Internal Combustion Engine (H2-ICE) displayed by Southwest Research Institute (SwRI) at SAE International's Commercial Vehicle Engineering Congress (COMVEC) in Schaumburg, Illinois.
The H2-ICE vehicle demonstrates emissions control capable of outperforming EPA/CARB 2027 and Euro 7 criteria pollutant emissions standards.
"The integration of our Allison 4000 Series in the H2-ICE vehicle demonstrates the critical role internal combustion engine (ICE) powertrain solutions can and will play in moving the industry closer to ultra-low emissions," said Ryan Milburn, Vice President, Product Engineering, Allison Transmission.

Novatus Global Secures $40 Million Growth Investment from Silversmith Capital Partners to Transform Transaction Reporting and Drive International Expansion Amid Complex Global Regulatory Environment

Retrieved on:

Thursday, September 12, 2024

Novatus Global Limited (“Novatus” or “the Company”), an award-winning provider of regulatory technology solutions to global financial institutions, today announced it has secured a $40 million investment from Silversmith Capital Partners , a Boston-based growth equity firm.

Key Points:

Novatus Global Limited (“Novatus” or “the Company”), an award-winning provider of regulatory technology solutions to global financial institutions, today announced it has secured a $40 million investment from Silversmith Capital Partners , a Boston-based growth equity firm.
Novatus enables its customers to meet their most complex, mission-critical regulatory and compliance requirements, be they government or industry-driven.
En:ACT is a fully-scalable, cloud-native platform trusted by major global firms to reconcile both source systems and submission files and for all G20 transaction reporting regimes.
Kirkland & Ellis served as legal counsel to Silversmith Capital Partners and KPMG served as financial advisors.

BioIVT to Host and Participate in Prominent Industry Events to Advance ADME Research

Retrieved on:

Thursday, September 12, 2024

Featuring researchers from academia, industry and BioIVT, the symposium will also highlight the new ICH M12 regulatory guidance and present recently published studies and other data on how complex models are being used to investigate the ADME-Tox properties of new drugs.

Key Points:

Featuring researchers from academia, industry and BioIVT, the symposium will also highlight the new ICH M12 regulatory guidance and present recently published studies and other data on how complex models are being used to investigate the ADME-Tox properties of new drugs.
BioIVT’s conference involvement includes the following:
Dr. Tina Mueller, BioIVT Scientific Advisor for ADMET Services, will present: “ The Potential of Psychedelics for the Treatment of Neuropsychiatric Disorders.
Attendees can visit the BioIVT team at booth #505.
“We are the global leader in providing products for in vitro ADME research and we have unparalleled expertise providing drug metabolism and drug-drug interaction studies and guidance.

Aduro Clean Technologies Reports 2024 Financial Results and Provides End of Year Update

Retrieved on:

Thursday, September 12, 2024

LONDON, Ontario, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Aduro Clean Technologies Inc. (“Aduro” or the “Company”) (CSE: ACT) (OTCQX: ACTHD) (FSE: 9D5), a clean technology company using the power of chemistry to transform lower value feedstocks, like waste plastics, heavy bitumen, and renewable oils, into resources for the 21st century, has filed its audited financial results for the year ended May 31, 2024, and has provided the following highlights. All financial information in this press release is reported in Canadian dollars, unless otherwise indicated.

Key Points:

Ofer Vicus, CEO of Aduro, remarked, “In 2024 the Company is focusing on execution, making sure we continue to make progress on our key goals.
Loss from operations was $1,792,219 for Q4 2024, as compared to loss from operations of $1,598,118 in Q4 2023.
Loss from operations was $7,436,861 for the fiscal year 2024, as compared to a Loss from operations of $5,863,317 for fiscal year 2023.
Aduro aims to complete the design of the NGP by the end of 2024.

Which gut drugs might end up in a lawsuit? Are there really links with cancer and kidney disease? Should I stop taking them?

Retrieved on:

Thursday, September 12, 2024

Lawyers are exploring whether long-term use of these over-the-counter and prescription drugs are linked to stomach cancer or kidney disease.

Key Points:

Lawyers are exploring whether long-term use of these over-the-counter and prescription drugs are linked to stomach cancer or kidney disease.
Specifically, patients claimed the company’s drugs Nexium (esomeprazole) and Prilosec (omeprazole) increased the risk of kidney damage.

Which drugs are involved in Australia?

In the case of the Australian potential class action, lawyers are investigating: Nexium (esomeprazole) Losec, Asimax (omeprazole) Somac (pantoprazole) Pariet (rabeprazole) Zoton (lansoprazole).
Depending on their strength and quantity, these medicines are available over-the-counter in pharmacies or by prescription.
These drugs are also prescribed with antibiotics to treat the bacterium Helicobacter pylori, which causes stomach ulcers and stomach cancer.

What do we know about the risks?

Like all medicines, there are risks associated with their use depending on how much and how long they are used.
When proton pump inhibitors are used appropriately for the short-term treatment of stomach problems, they are generally well tolerated, safe and effective.

How about the cancer and kidney risk?

Currently, the Australian consumer medicine information sheets that come with the medicines, like this one for esomeprazole, do not list stomach cancer or kidney injury as a risk associated with using proton pump inhibitors.
These studies have found people who take them are almost two times more likely to develop stomach cancer and 1.7 times more likely to develop chronic kidney disease when compared with people who are not taking them.
In particular, these studies report that users of the drugs lansoprazole and pantoprazole have about a three to four times higher risk than non-users of developing chronic kidney disease.

What can I do if I’m worried?

The documentary Killjoy captures the personal and the political of family violence and gender activism

Retrieved on:

Tuesday, September 10, 2024

ACT, Activism, History, Death, Life, Male, Government, Family, Racism, Physiology, Police, RESPECT, Risk, Australian Research Council, Pain, Domestic violence, Travel, Child, Jet fuel

To do this, they had to obtain their mother’s death certificate.

Key Points:

To do this, they had to obtain their mother’s death certificate.
Eight years of this journey are documented in the new Australian documentary Killjoy.

At home alone with a woman-killer

She had been having an affair with a fellow member of her local theatre club.
They were entrusted to the sole care of their father in the long period between him being charged and being tried.
For some years, Kathryn – by all accounts a physical likeness of their mother – lived alone with a woman-killer.

Finding a woman’s life in the historical archives

As all historians who try to trace the lives of women are aware, women still tend to be identified more with the private, domestic sphere.
Even when they are part of public conversation, their experiences are often mediated through a male lens.
As Kathryn was to discover, through past newspapers and interviews with Carolyn’s former friends, this was not the case in the 1980s.

Control and killjoys

Ultimately, Killjoy is a story about control.
But even in the states where it has been abolished, men still cite a loss of control when trying to excuse themselves of woman-killing.
Women do not control their fates when an unconscionable number of them continue to die at the hands of their intimate partners – there have been 47 violent deaths in Australia by September 6 this year.

Indiana Wesleyan University Partners with Advanced eClinical Training to Enhance Allied Health Education and Offerings

Retrieved on:

Tuesday, September 10, 2024

ACT, IWU, Health, Indiana Wesleyan University, Knowledge, Hospital, Student, Workforce, Partnership, Nursing

New York, New York--(Newsfile Corp. - September 9, 2024) - Advanced eClinical Training (ACT), a leading provider of online short-term healthcare training is proud to announce its partnership with Indiana Wesleyan University (IWU) aimed to enhance its allied health education and offerings.

Key Points:

New York, New York--(Newsfile Corp. - September 9, 2024) - Advanced eClinical Training (ACT), a leading provider of online short-term healthcare training is proud to announce its partnership with Indiana Wesleyan University (IWU) aimed to enhance its allied health education and offerings.
As the healthcare industry continues to evolve, the demand for skilled professionals in allied health roles has never been greater.
"We are thrilled to partner with Indiana Wesleyan University in advancing career-focused training programs in healthcare," said Cassidy Floyd, Director of Strategic Partnerships at Advanced eClinical Training (ACT).
Students interested in pursuing careers in allied health will benefit from this collaboration, which provides the essential training and certifications required to thrive in today's healthcare landscape.